Gliclazide MR. Multidisciplinary at-a-glance Review article
Article Sidebar
Published:
Sep 30, 2017
Keywords:
diabetes type 2, diabetic complications, hypoglycemia, gliclazide MR
Main Article Content
Abstract
One of the group of hypoglycemic agents applied to the treatment of diabetes for the last 50 years are sulfonylureas derivatives. Such a long period of use allow to complex assessment of it’s properties and clinical efficacy. In this group gliclazide MR in formulation which allows to once daily dosing stands up. A lot of clinical trials documented that gliclazide MR is effective in term of normalizing blood glucose, safe in term of hypoglycemia and diabetic complications. Application of gliclazide MR should be considered in every patient insufficiently treated with metformin.
Article Details
How to Cite
Strojek, K., Okopień, B., Bułdak, Łukasz, & Małecki , R. (2017). Gliclazide MR. Multidisciplinary at-a-glance. Medycyna Faktow (J EBM), 10(3(36), 206-209. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2124
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Gæde P., Vedel P., Larsen N. et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003; 348: 383-393.
2. DeFronzo R.: From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus.
3. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2017. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Kliniczna 2017; 3: supl. A.
4. Gæde P., Oellgaard J., Carstensen B. et al.: Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59: 2298-2307.
5. Gregorio F., Ambrosi F., Cristallini S. et al.: Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function. Diabetes Res. Clin. Pract. 1992; 18(3): 197-206.
6. Chan S.P., Colagiuri S.: Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res. Clin. Pract. 2015; 110(1): 75-81.
7. Proks P., Reimann F., Green N. et al.: Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51(supl. 3): S368-376.
8. Abdelmoneim A.S., Hasenbank S.E., Seubert J.M. et al.: Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes. Metab. 2012; 14(2): 130-138.
9. Ashcroft F.M., Gribble F.M.: Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J. Diabetes Complications 2000; 14(4): 192-196.
10. Schernthaner G.: Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism 2003; 52(8 supl. 1): 29-34.
11. Patel A.; ADVANCE Collaborative Group; MacMahon S., Chalmers J. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
12. Levey A.S., Cattran D., Friedman A. et al.: Proteinuria as a surrogate outcome in CKD: report of a scientific workshopsponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 2009; 54: 205-226.
13. Lee Y.H., Lee C.J., Lee H.S. et al.: Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes & Metabolism 2015; 41: 208-215.
14. Zoungas S., Chalmers J., Neal B. et al.; for the ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. Med. 2014; 371: 1392-1406.
15. Schernthaner G., Grimaldi A., Di Mario U.et al.: GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur. J. Clin. Invest. 2004; 34: 535-542.
16. Schramm T.K., Gislason G.H., Vaag A. et al.: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J. 2011; 32(15): 1900-1908.
2. DeFronzo R.: From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus.
3. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2017. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Kliniczna 2017; 3: supl. A.
4. Gæde P., Oellgaard J., Carstensen B. et al.: Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59: 2298-2307.
5. Gregorio F., Ambrosi F., Cristallini S. et al.: Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function. Diabetes Res. Clin. Pract. 1992; 18(3): 197-206.
6. Chan S.P., Colagiuri S.: Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res. Clin. Pract. 2015; 110(1): 75-81.
7. Proks P., Reimann F., Green N. et al.: Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51(supl. 3): S368-376.
8. Abdelmoneim A.S., Hasenbank S.E., Seubert J.M. et al.: Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes. Metab. 2012; 14(2): 130-138.
9. Ashcroft F.M., Gribble F.M.: Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J. Diabetes Complications 2000; 14(4): 192-196.
10. Schernthaner G.: Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism 2003; 52(8 supl. 1): 29-34.
11. Patel A.; ADVANCE Collaborative Group; MacMahon S., Chalmers J. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
12. Levey A.S., Cattran D., Friedman A. et al.: Proteinuria as a surrogate outcome in CKD: report of a scientific workshopsponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 2009; 54: 205-226.
13. Lee Y.H., Lee C.J., Lee H.S. et al.: Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes & Metabolism 2015; 41: 208-215.
14. Zoungas S., Chalmers J., Neal B. et al.; for the ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. Med. 2014; 371: 1392-1406.
15. Schernthaner G., Grimaldi A., Di Mario U.et al.: GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur. J. Clin. Invest. 2004; 34: 535-542.
16. Schramm T.K., Gislason G.H., Vaag A. et al.: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J. 2011; 32(15): 1900-1908.